Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 92 Lung Neoplasms 32 NSCLC 7 Brain Neoplasms 7 Meningeal Carcinomatosis 4 Neoplasm Metastasis 3 Carcinoma, Squamous Cell 2 Bronchial Neoplasms 2 Adenocarcinoma of Lung 2 Small Cell Lung Carcinoma 1 Sexual Dysfunction, Physiological 1 Resectable Non-small Cell Lung Cancer 1 Rare Tumour 1 Prostatic Neoplasms 1 Progression Free Survival 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-small Cell Carcinoma 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1 Non-Small Cell Lung Cancer With EGFR T790M Mutation 1 Non-Small Cell Lung Cancer With EGFR Mutation 1 Non Small Cell Lung Cancer Metastatic 1 Neurocognitive 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Lung Cancer Metastatic 1 Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1 Glioblastoma 1 Eunuchism 1 Erectile Dysfunction 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × osimertinib × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡